Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis by Todd, SK et al.
  
Regulatory B cells are numerically but not functionally deficient in anti-neutrophil 
cytoplasm antibody (ANCA) associated vasculitis 
S Katrina Todd
1
, Ruth J Pepper
1
, Juliana Draibe
1
, Anisha Tanna
2
, Charles D Pusey
2
, 
Claudia Mauri
3
, Alan D Salama
1
 
 
1
UCL Centre for Nephrology, Royal Free Hospital 
2
Renal and Vascular Inflammation Group, Imperial College London, Hammersmith 
Hospital 
3
Centre for Rheumatology, University College London 
Correspondence to:  Dr Alan D. Salama 
   UCL Centre for Nephrology 
   Royal Free Hospital 
   Rowland Hill Street 
London NW3 2PF 
Email: a.salama@ucl.ac.uk 
Tel: +442077940500 x36007 
Fax: + 4402078302653 
 
Short title: 
Numerical deficiency in B regulatory cells in AAV 
 
 
 
 
 
  
ABSTRACT 
Objective 
B cells are central to the pathology of ANCA-associated vascultitis (AAV), a disease 
characterised by autoantibodies and effectively treated by rituximab. In addition to promoting 
inflammation, a subset of B cells act to suppress harmful autoimmune responses (Breg). The 
balance of effector and regulatory B cell subsets in AAV is not known; this study was 
conducted to assess the relative frequency of these subsets during different states of disease 
activity.  
Methods 
B memory (Bmem), naïve and regulatory (Breg) subsets were defined by their relative 
expression of CD24 and CD38. Function was assessed by cytokine production and 
suppressive action on CD4+ Th1 activation, evaluated in a co-culture system.  
Results 
Compared to healthy controls, the frequency of Breg (CD24
hi
 CD38
hi
) was significantly 
reduced during disease remission and during acute disease in patients with PR3-ANCA, 
while the frequency of memory cells (Bmem, CD24
hi
 CD38
lo
) was reduced during active 
disease, and restored during remission. Breg cell frequency showed a positive correlation, 
whilst Bmem had an inverse correlation, with IL-10 production in vitro. B and T cell co-
cultures revealed that memory and naive B cell subsets augmented Th1 activation in vitro, 
which was prevented by Breg, and this pattern did not differ between remission AAV patients 
and controls. 
 
  
Conclusion 
In remission, there is a numerical, but not functional, deficiency in Breg and preservation of 
Bmem, associated with reduced IL-10 production and increased Th1 activation in vitro. This 
imbalance may contribute to the high rate of relapse observed in AAV. 
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INTRODUCTION 
Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitidies (AAV) are 
characterised by autoantibodies against myeloperoxidase (MPO-ANCA) or proteinase 3 
(PR3-ANCA).  Autoreactive B cells class switch and undergo somatic hyper-mutation within 
secondary lymphoid tissues, producing high affinity antibodies that directly contribute to 
pathogenesis (1-3). ANCA activate neutrophils and monocytes, promoting adherence to 
endothelial cells and degranulation, resulting in release of proteolytic granule proteins, 
cytokines and chemokines, culminating in further leukocyte recruitment and vascular damage 
(4). The importance of B cells in disease pathogenesis is further demonstrated by use of B 
cell depleting agents such as rituximab, shown to induce clinical remission with similar 
efficacy to cyclophosphamide (5, 6).  
 
B cells can modulate immunity independently of antibody production. They are effective 
antigen presenting cells (7), and  a potent source of cytokines, shaping the CD4 T cell 
response (8). Some B cell subsets may act to limit inflammation, this function has been 
attributed to the CD19+ CD38
hi
 CD24
hi
 population of B regulatory cells (Bregs) (9-11). 
Bregs suppress T cell proliferation and production of pro-inflammatory cytokines in vitro, 
partly mediated by interleukin 10 (IL-10) and dependent on direct T cell contact (11). Other 
inhibitory mechanisms may include production of TGF-beta and inhibitory antibodies (12). 
In this study we set out to assess the balance of the different B cell subsets, Breg (CD38
hi
 
CD24
hi
), B memory (Bmem, CD38
lo 
CD24
hi
) and naïve B cells (Bnaive, CD38
int
 CD24
int
 (10, 
11), in an AAV cohort during different disease states.  
 
 
 
  
MATERIALS AND METHODS 
Subjects 
Samples were obtained in accordance with the 1975 Declaration of Helsinki, after informed 
patient consent and under local ethical approval (05/Q0508/6). All patients fulfilled the 
Chapel Hill definitions for granulomatosis with polyangiitis (GPA) or microscopic 
polyangiitis (MPA) (13). The study group comprised 19 healthy controls and 58 patients, 
categorised by disease activity. Acute samples were obtained at the time of initial 
presentation. Remission was defined as the complete absence of clinical disease attributable 
to vasculitis, minimum of one month. Tolerant patients were classified as those with a history 
of active AAV, who subsequently became negative for ANCA by ELISA, remaining free 
from pathology after withdrawal of treatment for a minimum of 2 years.  
 
Cell isolation and enrichment 
Peripheral blood mononuclear cells (PBMC) were isolated from venous blood by gradient 
centrifugation on lymphoprep (Alere, Stockport, UK). B cell subsets were isolated from 
PBMC by cell sorting on a BD FACSAria (BD Biosciences). Cells were selected on the basis 
of DAPI (4', 6-diamidino-2-phenylindole) exclusion (Sigma-Aldrich, Dorest, UK) and relative 
expression of CD19, CD24 and CD38.CD4+CD25- T cells were isolated by serial CD25 and 
CD4 magnetic bead isolation on MS columns (Miltenyi Biotec, Surrey, UK).  
 
B cell immunophenotyping 
PBMC were stained with CD19 [HIB19], CD24 [eBioSN3] and CD38 [HIT2] antibodies 
(eBioscience Ltd, Hatfield, UK). Acquisition was performed on an LSRFortessa instrument 
(BD Bioscience).  Flow cytometry analysis was conducted using FlowJo version 7.6.3. 
  
(TreeStar, Ashland, OR, USA). B cell frequencies were expressed as corrected percentages, 
with the sum equal to 100%, excluding the contribution of CD19+ CD24- cells, previously 
described (14, 15). 
 
B cell IL10 and TNF-α  production 
B cell IL-10 production was assessed in a subset of individuals from the main cohort: 12 
remission patients (5 male, 8 PR3-ANCA, 3 MPO-ANCA, 1 ANCA negative); 4 rituximab-
treated patients (2 male, 4 PR3-ANCA) and 8 controls (4 male). PBMCs were cultured in 
RPMI 1640 supplemented with 2mM L-glutamine (Life Technologies Ltd, Paisley, UK) and 
10% FCS (Sigma-Aldrich), for 48 hours at 37ºC and 5% CO2. Untreated cells were compared 
with CpG- stimulated cells(40µg/ml ODN 2006-G5 (InvivoGen, San Diego, CA, USA)), with 
or without CD154(4µg/ml CD154 and 10 µg/ml cross-linking antibody (R&D systems, 
Abingdon, UK)).  For the last 5 hours Golgi-Plug (BD Bioscience) was added, with 50ng/ml 
phorbol myristate acetate (PMA) and 1µg/ml inomycin (Sigma-Aldrich). 
Viability was assessed with BD Horizon™ Fixable Viability Stain (BD Biosciences). CD19 
cell surface staining was performed and intracellular staining conducted according to the 
manufacturer’s instructions (eBioscience fixation and permeablisation kit), with IL-10 [JES3-
9D7] (Biolegend, London, UK) and TNF-α [MAb11] (eBioscience) antibodies. Sample 
acquisition as described.  
 
B cell co-cultures 
Effects on T cell activation were assessed in a subset of individuals from the main cohort: 5 
remission patients (1 male, 2 PR3-ANCA, 3 MPO-ANCA) and 5 controls (4 male). CD4+ 
  
CD25- T cells were cultured alone or with B cell subsets, at a fixed ratio of 4:1 T:B cells in 
RPMI 1640, supplemented with: 2mM L-glutamine, 10% FCS, NEAA (Fisher, 
Loughborough, UK), 1mM sodium pyruvate (Sigma-Aldrich) and penicillin/streptomycin 
(Life Technologies Ltd).   
T cells were stimulated with soluble anti-CD28 [CD28.8] at 2µg/ml (eBioscience) and plate 
bound anti-CD3 [HIT3a] (BD Biosciences, 10µg/ml). Unstimulated T cells were included as 
a control.  Cells were cultured for 5 days at 37ºC and 5% CO2. For the last 4 hours, 50ng/ml 
PMA and 1µg/ml inomycin (Sigma-Aldrich) were added to CD3/28 stimulated cells and 
Golgi-Plug and Stop added to all wells (BD Bioscience). 
Viability was assessed and staining conducted for CD4 [SK3] (Biolegend), as previously 
described. Cells were fixed in 4% PFA and permeablised in 0.5% saponin (Sigma Aldrich). 
Staining was conducted for IFN-γ [4S.B3] (Biolegend) and TNF-α [MAb11] (eBioscience), 
for 40 minutes on ice, in 0.1% saponin (Sigma Aldrich). Sample acquisition and analysis as 
described; results expressed as percentage change, relative to T cells cultured alone 
(normalised to zero) 
 
Statistical analysis 
Statistical analyses were performed in GraphPad Prism version 6 (GraphPad Software, Inc., 
San Diego, CA). Chi-Square was performed for discrete variables; 1-way ANOVA to 
compare single parameters in multiple test groups; 2-way ANOVA to compare multiple 
parameters in patients and controls. Mann Whitney U test was used when comparing two 
groups, for a single parameter. Regression analyses were performed, as indicated; correlation 
was assessed by Spearman rank. 
  
RESULTS 
AAV and control subjects  
The control group comprised 10 males and 9 females, and did not differ from the AAV 
cohort. The median age of the controls was 50 years (IQR 40-60), which differed only from 
the remission group at 65 years (52-75) (p=0.0083). The characteristics of 51 patients are 
summarised in Table 1, separated according to disease activity. Rituximab treated patients 
were in clinical remission (n=7), but their demographics and results are provided in Table 2. 
Analysis of this group was performed separately, due to the profound effects of therapy on B 
cell homeostasis.  
 
TABLE 1 Comparison of patients, according to disease activity 
 
Diagnosis and ANCA specificity did not differ and there was no difference in total 
lymphocyte count between the groups. The remission group contained a higher proportion of 
women and had lower serum creatinine than active or tolerant groups. With regards time 
from diagnosis, samples were taken from acute patients at time of initial presentation, but 
there was no difference between remission and tolerant patients. Standard induction therapy 
in acute patients was high dose prednisolone and cyclophosphamide. Maintenance therapy in 
remission comprised azathioprine or mycophenolate mofetil, in combination with low dose 
prednisolone. 
 
 
 
  
Differences in B cell subset distribution, according to disease activity 
Breg percentage frequency was reduced in remission but not in tolerant or acute patients, 
relative to controls (P=<0.0001, Figure 1A). We observed reduced Bmem in acute disease 
(P=0.0145) but no decline in Bmem in remission and a trend towards lower Bmem frequency 
in tolerant patients (P=0.0698), compared to controls (Figure 1B). We represented the 
imbalance in effector and regulatory subsets by a memory: regulatory ratio, denoted M:Rn. 
This was derived by dividing the absolute number of cells within the Bmem gate by the 
number within the Breg gate. M:Rn  was significantly increased in remission subjects (19.8, 
IQR 6.6-45.2), compared to controls (5.1, IQR 2.9-9.4)(P=0.0008, Figure 1C). While we 
cannot exclude the influence of treatment on B cell subsets, the total lymphocyte counts did 
not differ between AAV and control subjects (Table 1), and we found no significant 
differences in B cell subsets according to immunosuppressive treatment (Supplementary 
figure 1), in agreement with recent data, in which cyclophosphamide did not affect CD19+ 
CD38
hi
 CD24
hi
 B cell frequency (16).  
 
B cell subsets in PR3- and MPO-ANCA disease 
When we examined distribution of B cell subsets according to ANCA specificity, we found 
Bmem frequency was higher in remission patients with PR3-ANCA (37.4, IQR 27.7-52.8), 
than MPO-ANCA patients (27.7, IQR 9.7-41.0) (P=0.0382, Figure 1B). However, M:Rn did 
not differ between these groups (Figure 1C). In acute disease, there was no significant 
difference in Bmem frequency according to ANCA subtype, but frequency of Breg  was 
reduced in PR3-ANCA patients (2.7, IQR 2.0-2.9) compared with MPO-ANCA (5.9, IQR 
4.2-9.6) (P=0.0101, Figure 1A). 
  
FIGURE 1  Disruption of B cell homeostasis in AAV 
 
Outcome data 
Within the remission group, 12 month clinical follow up was available for 24 patients; 3 
relapses were recorded, all in PR3-ANCA patients, enabling a comparison of PR3-ANCA 
positive patients who relapsed (n=3), with those who did not (n=6). Bmem numbers and 
frequency of CD19 cells within the lymphocyte gate, were statistically higher in those who 
relapsed, compared to those who did not (P=0.0238 and 0.0476 respectively).  We observed a 
tendency towards lower Breg frequency in relapsing patients (IQR 0.4-1.7), compared to 
those in stable remission (IQR 1.4-3.5), but this did not reach statistical significance. In 
addition 5 out of the 6 patients in stable remission had an M:Rn, below the lower 95% 
confidence interval for whole PR3-ANCA remission cohort(<15.2), whereas all those who 
went on to relapse had an M:Rn above the upper 95% confidence interval (>37.8). 
 
Effects of rituximab treatment on B cell subsets  
The median time from treatment with rituximab was 16 months, ranging from 6 months to 7 
years (Table 2). Flow cytometry plots before and after rituximab illustrate the profound 
changes that occur within the B cell populations (Figure 2A). The reduction in Bmem and 
increase in Breg were statistically significant compared with controls (Figure 2B). These 
changes continued after B cell repopulation within the lymphocyte gate. Effects were 
sometimes long-lasting, with increased Breg frequency observed in one patient 5 years after 
rituximab treatment, longer than previously reported (9). 
 
  
TABLE 2 B cell subsets following rituximab therapy 
 
FIGURE 2 Effects of rituximab on B cell subsets 
 
 
B cell cytokine profile in AAV 
In CPG-treated PBMC there was no difference in induction of IL10 positive B cells. When 
PBMC were treated with CD154 in addition to CPG, there was a dramatic increase in the 
frequency of IL10+ B cells compared to CPG alone (fold-increase 4.9, IQR 3.2-7.7). There 
remained no significant difference between controls and remission patients, but rituximab 
patients had a significantly higher frequency of IL10+ B cells than controls (P=0.0090) or 
remission patients (P=0.0347). 
B cell IL-10 induction upon CPG and CD154 stimulation was proportionate to Breg and 
inversely proportionate to Bmem frequency (Figure 3C).  Rituximab-treated patients had 
higher frequency of Breg (29.4, IQR 15.1-44.5) and lower frequency of Bmem (5.7, IQR 3.1-
11.2), compared to controls or remission patients (1-way ANOVA, P=0.0140 and P=0.0108), 
accounting for the increased frequency of IL10+ B cells.   
The stimulation used to induce IL-10, also resulted in strong TNF-α expression within the B 
cell population (Figure 3A and B). On CPG treatment, TNF-α expression was lower in 
rituximab treated patients ( Median MFI 668, IQR 415-986) compared to remission patients 
(Median MFI 1370, IQR 917-1827) or controls (1112, IQR 868-1238), but this effect was lost 
upon CD154 stimulation (Figure 4B). 
 
  
FIGURE 3 B cell cytokine profile 
 
Effects of B cell subsets on Th1 activation 
B cell subsets used in the T cell co-cultures, ranged in purity from 83-100%, with a median 
value of 93% (Figure 4A). Inhibition of IFN-γ or TNF-α  cytokine production by CD4+ T 
cells following addition of Breg at a ratio of 1:4  did not reach statistical significance, but was 
in keeping with previously reported results in which  a Breg dose dependent effect was 
demonstrated, with maximum inhibition at a 1:1 ratio (11). We were unable to increase the 
proportion of Breg further, due to limited numbers of B cells. However, we were able to 
assess whether there was any variation in CD4 cytokine production between the different B 
cell subset co-cultures. We did so by expressing results as percentage difference relative to 
CD4+ CD25- T cell stimulation alone (Figure 4B and 4C). Importantly, no difference was 
observed in suppression between remission patients and healthy controls, (2-way ANOVA); 
this enabled patient and control data to be combined (n=10) for subset analysis 
Within this combined data set, there was a significant difference between the B cell subsets 
(results expressed as mean + standard deviation). The percentage of TNF-α positive T cells 
was increased in Bmem (5.40 +6.223) and Bnaive (6.28 +3.500) co-cultures, relative to Breg 
(-5.13 +2.652 ), (P= 0.0362). The frequency of IFN-γ positive CD4 cells was also increased 
in Bmem (25.30 +5.515) and Bnaive (18.03 +2.510) co-cultures, compared to Breg  (-4.23 
+5.621), (P= 0.0219). The results indicate that Bmem and Bnaive cells promote Th1 cell 
differentiation in vitro, whereas Breg have an opposite effect. 
 
FIGURE 4 Effects of B cell subsets on Th1 differentiation 
 
 
  
DISCUSSION 
The overall balance of B effector and regulatory cells is likely to be important in determining 
clinical outcome in AAV. Bmem have increased ability to stimulate T cells and can readily 
differentiate into plasmablasts on re-encountering antigen (14). The profile of cytokines 
produced by Bmem also differs, with higher lymphotoxin and TNF-α (17). In contrast, Breg 
produce IL-10 and TGF-beta (18), limiting differentiation and proliferation of pro-
inflammatory cells (11, 15, 19-21).  
 
We found Breg to be profoundly diminished in clinical remission, with restoration of Bmem; 
this imbalance was summarised by the M:Rn. Ratio.  M:Rn was  increased in remission 
patients, reduced following rituximab therapy and in patients who regained immunological 
tolerance. In patients who relapsed within 12 months of initial immunophenotyping, M:Rn 
was greater than the upper 95% confidence interval. The overall balance of B cell subsets 
determined frequency of IL-10 B cells, central to suppression of harmful Th1 and Th17 
autoimmune responses in vivo (19).  In addition, Bmem and Bnaive augmented Th1 
differentiation in vitro, whilst Breg did not.  
 
We found no difference in M:Rn during acute disease relative to controls; this might be due to 
B cell recruitment to the site of inflammation, terminal B cell differentiation with loss of 
CD19  expression or existence of a Bmem population with a non-classic phenotype.  CD27- 
IgD- double negative Bmem have previously described in systemic lupus erythematous, with 
low expression of CD38 and CD24 (22). 
 
We utilised  CD24 and CD38 to define Breg, however suppressive activity has also been 
attributed to CD5+ CD1d
hi
 cells, CD25+ and CD27+  B cells (12, 23-25).This study adds to 
  
the evidence that regulatory B subsets are diminished in AAV, but includes functional 
characterisation, previously lacking (16, 26-28). Eriksson el al found CD25+ B cells to be 
increased in clinical remission relative to acute disease (26), but they did not detect any 
deficit in Bmem cells (Bm5 or CD27+ cells), in contrast to Tadema et al (29). Bunch et al 
described a numerical deficiency in CD5+ B cells compared to controls, most profound 
during active disease (27). Although enriched for CD24
hi
 CD38
hi
 cells, CD5 B cells are 
present in the periphery at a higher frequency than Breg, and have previously shown to 
overlap with Bmem and Bnaive (30). When we segregated results according to antibody 
specificity, we found Breg reduced in acute PR3-ANCA patients, compared to both MPO-
ANCA patients and controls. The discrepancy between Bunch’s results and our own might 
therefore be due to a higher proportion of PR3-ANCA patients in their active cohort.   
 
We found no difference in IL-10 production in patients and controls, in contrast to Wilde et 
al.  However, this  cohort consisted of 78% PR3-ANCA subjects (28), in which we found 
lower Breg and higher Bmem, correlating with diminished IL-10 production. IL-10 
production in B cells may also be accompanied by pro-inflammatory cytokine production, 
including IL-4, IL-6, IL-12 and IFN-γ (21, 31). We demonstrate global expression of TNFα 
on CPG treatment. Thus, some IL-10 positive B cells may have a net pro-inflammatory 
effect, necessitating a combination of phenotypic and functional studies to define their role.  
 
In our suppression assays, there was a modest reduction Th1 cytokine production on addition 
of Breg. We conducted co-cultures over 5 days, with anti-CD28 and anti-CD3 stimulation, a 
stronger stimulus than that employed by Blair et al (11). Although the suppressive capacity of 
Breg on global T cell stimulation was limited, they remained unable to augment Th1 
differentiation. In contrast, we found addition of Bmem or Bnaive cells increased the 
  
production of proinflammatory cytokines by T cells. Augmentation of Breg frequency in 
tolerant patients and following rituximab treatment, may therefore limit B cell mediated Th1 
activation in vivo.  
 
Breg are thought to act in an antigen specific manner. B cell receptor (BCR) signalling is 
dependent on CD19 and is followed by increase in intracellular calcium. In CD19
-/-
 mice IL-
10 production is reduced and experimental autoimmune encephalomyelitis (EAE) 
exacerbated (32, 33).  Mice deficient for the endoreticular calcium sensors also have 
increased EAE severity, with altered splenocyte cytokine profile ex vivo (34). Addition of 
anti-IgM has been shown to  increase B cell IL-10 production in vitro (21), with infusion of 
treated B cells protecting mice from diabetes (35). Furthermore, in an animal model of 
contact hypersensitivity, B cell mediated protection was only conferred when mice were re-
challenged with the same stimulus (36). 
 
In vitro studies with human cells provide further evidence that Breg are antigen specific and 
require direct T cell contact as suppressive capacity is reduced in transwell cultures (11, 20). 
Allergen specific B cells have 30.8 fold higher expression of IL-10 mRNA, than non-antigen-
specific cells and are highly effective at reducing T cell division induced by a recall 
antigen(24), possibly indicating that Breg inhibit antigen specific T cell proliferation more 
potently than CD3 induced division. In AAV the antigen is known in the vast majority of 
patients (MPO or PR3); induction of antigen specific Breg ex vivo might therefore be 
possible, and could represent an effective therapeutic strategy for AAV. 
 
 
 
  
KEY MESSAGES 
1. B cell homeostasis is disturbed in AAV, with imbalance in memory and regulatory 
cells 
2. The balance of regulatory and memory subsets, determines frequency of IL-10 positive 
B cells  
3. Regulatory cells limit Th1 differentiation, whilst effector subsets augment TNFα and 
IFN γ production 
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Table 1 Comparison of patients, according to disease activity 
Patient characteristics Remission Acute Tolerant P-value 
Number  33 14 4  
Age 
 
Median  
IQR 
65  
52-75 
64 
49-71 
73  
52-83 
0.3200 
 
Sex (n) Male:Female  9:24 8:6 3:1 0.0495 
Lymphocyte count  
 
Median (x10
9
/L) 
IQR 
1.4 
0.8-1.8 
1.0 
0.7-1.7 
1.5 
1.1-1.8 
0.5629 
 
Serum creatinine   
 
Median (mg/dL)  
IQR 
98 
63-155 
152 
124-503 
220 
134-316 
0.0038 
 
Diagnosis  MPA:GPA(n)  19:14 10:4 3:1 0.5811 
Point of diagnosis   Median (years) 6 0 11 0.0010 
ANCA specificity  
 
PR3 (n) 
MPO (n) 
18 
12 
7 
6 
1 
3 
0.5343 
 
Treatment (n) None 2 3  0.1181 
 
Cyclophosphamide 1 6  0.0005 
 
Mycophenolate  6 0  0.0876 
 
Methotrexate 2 2  0.8541 
 
Azathioprine 18 1  0.0025 
Corticosteroids 21 11  0.3151 
Oral prednisolone  Median  dose (mg) 5.0 37.5 
 
<0.0001 
 
Statistical analyses were performed to compare patient groups: Chi-square for discrete 
variables and 1-way ANOVA for continuous variables, significance assumed at P≤0.05. 
  
Table 2 B cell subsets following rituximab therapy 
Age Sex ANCA Time Since RTX CD19 % Bmem % Breg % M:Rn 
48 F PR3 1.2 0.359 2.6 27.7  0.092 
34 M PR3 0.6 0.095 1.5 42.0 0.036 
71 M PR3 5 1.75 4.7 27.5 0.171 
65 M PR3 1.2 4.2 6.9 31.0 0.223 
47 M PR3 8 4.61 12.6 10.9 1.161 
52 F PR3 1 5.77 4.6 48.2 0.095 
16 F MPO 7 7.89 20.8 6.8 3.052 
 
Time since last rituximab (RTX) infusion shown in years, median 16 months. CD19 
percentage corresponds to frequency of B cells within the lymphocyte gate. Bmem and Breg 
shown as corrected percentages, M:Rn calculated as previously described. 
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FIGURE LEGENDS 
Figure 1. Disruption of B cell homeostasis in AAV 
[A] Breg reduced during remission relative to controls (P=0.0001). Breg also reduced in 
acute PR3-ANCA disease, relative to acute MPO-ANCA (P=0.0101) or controls (P=0.0017). 
No significant difference (NS) between MPO-ANCA and PR3-ANCA patients, during 
remission. [B] Bmem reduced in acute disease relative to controls (P=0.0121, with trend in 
tolerant subjects (P=0.0624). No significant difference in Bmem during remission relative to 
controls but Bmem higher in PR3-ANCA than MPO-ANCA (P=0.0382). [C] M:Rn increased 
in remission, with high values observed in both MPO-ANCA and PR3-ANCA.. M:Rn higher 
in acute PR3-ANCA than MPO-ANCA (P=0.0025) (* P<0.05, *** P<0.001, **** 
P<0.0001).  
 
Figure 2. Effects of rituximab on B cell subsets 
[A] Flow cytometry plots from 2 patients before (left hand side) and after rituximab 
treatment (right hand side). After B cell repopulation Bmem (CD24hi CD38lo) and Bnaive 
cells are diminished (CD24int CD38int); the majority of B cells have a regulatory phenotype 
(CD24hi CD38hi). [B] Rituximab treated patients have statistically lower frequency of Bmem 
(P=0.0004) and higher frequency of Breg (P=0.0006) than controls (n=19); Mann Whitney U 
test (*** P<0.001). Box and whiskers plots show minimum and maximum values, rituximab 
data points also provided in Table 2 (n=7). 
 
Figure 3. B cell cytokine profile in CPG and CD154 treated PBMC 
[A] Quadrants drawn so ≤1% positivity in control (BFA, Brefeldin A). Treatment resulted in 
global production of TNFα: BFA (filled), CPG (dashed line), CPG and CD154 (black 
line). [B] Frequency of IL10 positive B cells did not differ on CPG treatment; on addition 
  
of CD154 frequency was higher in rituximab group than controls (P=0.0071) or 
remission(P=0.0191). TNFα MFI was lower in rituximab group upon CPG stimulation, than 
remission(P=0.0097), statistical significance lost on addition of CD154 [C] Frequency of 
IL10positive B cells upon CPG and CD154 stimulation, was proportionate to Breg 
(P=0.0043)and inversely correlated with Bmem (P=0.0027) (* P<0.05, ** P<0.01). 
 
Figure 4. Effects of B cell subsets on Th1 differentiation 
The cohort comprised 10 individuals, however a single data point was missing for 2 of the 
controls (Bnaive and Breg, n=9). [A] There was modest decrease in cytokine positive CD4 
cells with Breg and increase, in Bmem and Bnaive co-cultures (2-way ANOVA, TNFα 
P=0.0362 and IFNγ P=0.0219, * P<0.05). [B] MFI was also reduced in Breg and increased, in 
Bmem and Bnaive co-cultures (2-way ANOVA, TNFα and IFN-γ ****P<0.0001). The 
change in MFI differed between patients and controls for IFNγ, but not TNFα. The increase 
in IFNγ MFI was less in patient Bmem (P=0.0310) and Bnaive (P=0.0175) co-cultures(Holm-
Šidak’s multiple comparison) 
 
 
